RobertBLorsbachMD
Pathology • Cincinnati, OHHematopathology, Anatomic Pathology, Clinical Pathology
Associate Professor, Pathology, University of Arkansas COM
Dr. Lorsbach is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3333 Burnet Ave
ML 1010
Cincinnati, OH 45229Phone+1 513-636-4261Fax+1 513-636-3026
Education & Training
Brigham and Women's HospitalFellowship, Hematopathology, 1998 - 1999- Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1994 - 1998
University of Kansas School of MedicineClass of 1994
Certifications & Licensure
OH State Medical License 2014 - 2026
AR State Medical License 2006 - 2014
TN State Medical License 1999 - 2007
MA State Medical License 1998 - 2000
American Board of Pathology Anatomic Pathology- American Board of Pathology Hematology
Publications & Presentations
PubMed
- Granulomatous Variant of Giant Centrifugal Miliaria Profunda in an 8-Month-Old Boy: Expanding the Dermatologic Phenotype of Cardiofaciocutaneous Syndrome.Hannah C Tolson, Fatmah Alzahrani, Raj Singh, Robert Lorsbach, Theresa A Grebe
Pediatric Dermatology. 2025-01-22 - 9 citationsDabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.Eily Cournoyer, Justin Ferrell, Susan Sharp, Anish Ray, Michael Jordan
Haematologica. 2024-04-01 - Pediatric myelofibrosis due to compound heterozygous MPIG6B mutations in a patient of European ancestry.Leonard N Yenwongfai, Ranjana Arora, Alexander P Smith, Theodosia Kalfa, Ammar Husami
Pediatric Blood & Cancer. 2023-03-01
Abstracts/Posters
- Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR)Robert B. Lorsbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute LeukemiaRobert B. Lorsbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- VPS4A mutations Cause a Syndrome with Dyserythropoiesis, Hemolytic Anemia, and Neurodevelopmental DelayRobert B. Lorsbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
